Pentair expands in sterile air filtration with Carl Prandtl acquisition

Pentair expands in sterile air filtration with Carl Prandtl acquisition

NEWS/EXCHANGE RATES Parker buys railroad filtration business from Camfil Farr P arker Hannifin Corp has acquired Camfil Farr Group’s railroad filtr...

67KB Sizes 0 Downloads 69 Views

NEWS/EXCHANGE RATES

Parker buys railroad filtration business from Camfil Farr

P

arker Hannifin Corp has acquired Camfil Farr Group’s railroad filtration business, a manufacturer of air and liquid filtration products used in rail and transit, mining and marine engine applications. Headquartered in Laval, Canada, the Camfil Farr railroad filtration business had sales of approximately US$22 million in 2011, 90 employees and operations and sales in Canada, Mexico and India and a sales presence in the US and Australia. The acquired business will become part of Parker’s Filtration Group. About 75% of the ongoing revenues of the railroad filtration business will be reported in Parker’s Industrial North America reporting segment, while the remaining 25% will be reported in the company’s Industrial International segment. “Parker sees significant opportunities to broaden our large engine and air filtration product lines and leverage products in other large combustion engine applications,” said Peter Popoff, president of Parker Hannifin’s Filtration Group. “The railroad business of Camfil Farr brings expertise and services that allow Parker’s Filtration Group to build a worldwide presence in specialised rail, marine and mining markets, while adding clean air technologies to strengthen our fil-

tration solutions capabilities. Additionally, this transaction will give Parker Filtration manufacturing capacity in Canada and Mexico to better service customers in those markets.” For further information, visit www.parker.com and www.camfilfarr.com

Pentair expands in sterile air filtration with Carl Prandtl acquisition

P

entair Filtration Solutions has acquired Carl Prandtl MicroFiltration (CPM), a German specialist in sterile air filtration technology for the food and beverage industry. “This acquisition will further Pentair’s leadership position in the attractive food and beverage sector, where Pentair Filtration Solutions’ expertise is already highly valued,” said Netha Johnson, president of Pentair Filtration Solutions. Olaf Müller, vice president Food & Beverage, added: “By broadening our technology and components portfolio in Food and Beverage, we will be able to provide more integrated solutions to our customers.”

For further information, visit www.pentair.com and www.cpm-prandtl.de

Exchange Rates against the US Dollar Date: 21.2.2012 Country Australia

Rate A$0.94

Country Netherlands

Austria

E0.76

Norway

Belgium

E0.76

Philippines

C$1.00

Singapore

Canada

Rate E0.76 NOK5.67 Peso42.69 S$1.26

China

CNY6.30

South Africa

R7.72

Denmark

DKK5.62

South Korea

KWn1127.31

Finland

E0.76

Spain

France

E0.76

Sweden

SEK6.65

Germany

E0.76

Switzerland

CHF0.91

Taiwan

T$29.56

Thailand

Bt30.59

India Italy

Rp49.29 E0.76

Japan

¥80.14

UK

Malaysia

Rt3.03

USA

16

Filtration Industry Analyst

E0.76

£0.64

Editorial Office: Elsevier Limited The Boulevard, Langford Lane Kidlington Oxford OX5 1GB United Kingdom Tel: +44 (0) 1865 843695 Fax: +44 (0) 1865 843973 Web: www.filtrationindustryanalyst.com Editor: Roisin Reidy E-mail: [email protected] Production Support Manager: Lin Lucas E-mail: [email protected] Publisher: Greg Valero E-mail: [email protected] Subscription Information An annual subscription to Filtration Industry Analyst includes 12 issues and online access for up to 5 users. Prices: 1232 for all European countries & Iran US$1382 for all countries except Europe and Japan ¥163 800 for Japan (Prices valid until 31 December 2012) To subscribe send payment to the address above. Tel: +44 (0)1865 843687 or via www.filtrationindustryanalyst.com Subscriptions run for 12 months, from the date payment is received. Permissions may be sought directly from Elsevier Global Rights Department, PO Box 800, Oxford OX5 1DX, UK; phone: +44 1865 843830, fax: +44 1865 853333, email: [email protected]. You may also contact Global Rights directly through Elsevier’s home page (www.elsevier.com), selecting first ‘Support & contact’, then ‘Copyright & permission’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA; phone: +1 978 750 8400, fax: +1 978 750 4744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; phone: +44 (0)20 7631 5555; fax: +44 (0)20 7631 5500. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the Publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher. Address permissions requests to: Elsevier Science Global Rights Department, at the mail, fax and email addresses noted above. Notice No responsibility is assumed by the Publisher for any injury and/ or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Digitally Produced by Mayfield Press (Oxford) LImited 12976

US$1.00

February 2012